Your browser doesn't support javascript.
loading
SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders.
Cnossen, Marjon H; van Moort, Iris; Reitsma, Simone H; de Maat, Moniek P M; Schutgens, Roger E G; Urbanus, Rolf T; Lingsma, Hester F; Mathot, Ron A A; Gouw, Samantha C; Meijer, Karina; Bredenoord, Annelien L; van der Graaf, Rieke; Fijnvandraat, Karin; Meijer, Alexander B; van den Akker, Emile; Bierings, Ruben; Eikenboom, Jeroen C J; van den Biggelaar, Maartje; de Haas, Masja; Voorberg, Jan; Leebeek, Frank W G.
Affiliation
  • Cnossen MH; Department of Pediatric Hematology and Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • van Moort I; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Reitsma SH; Department of Pediatric Hematology and Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • de Maat MPM; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Schutgens REG; Center for Benign Hematology, Thrombosis and Hemostasis ,Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Urbanus RT; Center for Benign Hematology, Thrombosis and Hemostasis ,Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Lingsma HF; Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Mathot RAA; Department of Hospital Pharmacy-Clinical Pharmacology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Gouw SC; Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Meijer K; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Bredenoord AL; School of Philosophy, Erasmus University Rotterdam, The Netherlands.
  • van der Graaf R; Julius Center for Health Sciences and Primary Care, Department of Medical Humanities, University Medical Center Utrecht, the Netherlands.
  • Fijnvandraat K; Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Meijer AB; Sanquin Research, Department of Molecular Hematology, Amsterdam, The Netherlands, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • van den Akker E; Sanquin Research, Department of Molecular Hematology, Amsterdam, The Netherlands, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Bierings R; Sanquin Research, Department of Hematopoiesis, Amsterdam, The Netherlands, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Eikenboom JCJ; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • van den Biggelaar M; Department of Internal Medicine, Division of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, The Netherlands.
  • de Haas M; Sanquin Research, Department of Molecular Hematology, Amsterdam, The Netherlands, and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
  • Voorberg J; Sanquin Diagnostic Services and Center for Clinical Transfusion Research, Amsterdam, The Netherlands.
  • Leebeek FWG; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
J Thromb Haemost ; 2022 Jun 02.
Article in En | MEDLINE | ID: mdl-35652368
ABSTRACT

BACKGROUND:

Treatment choices for individual patients with an inborn bleeding disorder are increasingly challenging due to increasing options and rising costs for society. We have initiated an integrated interdisciplinary national research programme.

OBJECTIVES:

The SYMPHONY consortium strives to orchestrate personalized treatment in patients with an inborn bleeding disorder, by unravelling the mechanisms behind inter-individual variations of bleeding phenotype. PATIENTS The SYMPHONY consortium will investigate patients with an inborn bleeding disorder, both diagnosed and not yet diagnosed.

RESULTS:

Research questions are categorized under the themes 1) Diagnosis; 2) Treatment; and 3) Fundamental research and consist of workpackages addressing specific domains. Importantly, collaborations between patients and talented researchers from different areas of expertise promise to augment the impact of the SYMPHONY consortium, leading to unique interactions and intellectual property.

CONCLUSIONS:

SYMPHONY will perform research on all aspects of care, treatment individualization in patients with inborn bleeding disorders as well as diagnostic innovations and results of molecular genetics and cellular model technology with regard to the hemostatic process. We believe that these research investments will lead to health care innovations with long-term clinical and societal impact. This consortium has been made possible by a governmental, competitive grant from the Netherlands Organization for Scientific Research (NWO) within the framework of the NWA-ORC Call grant agreement NWA.1160.18.038.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country:
...